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We have successfully developed a practical approach to predicting the location of skin 
surface dose at potential biopsy sites that receive 1 cGy and 10 cGy, respectively, in 
support of in vivo biologic dosimetry in humans.  This represents a significant technical 
challenge as the sites lie on the patient surface out side the radiation fields.  The 
PEREGRINE Monte Carlo simulation system was used to model radiation dose delivery 
and  TLDs were used for validation on a phantom and confirmation during patient 
treatment.  In the developmental studies the Monte Carlo simulations consistently 
underestimated the dose at the biopsy site by approximately 15% for a realistic treatment 
configuration, most likely due to lack of detail in the simulation of the linear accelerator 
outside the main beam line.  Using a single, thickness-independent correction factor for 
the clinical calculations, the average of 36 measurements for the predicted 1 cGy point 
was 0.985 cGy (standard deviation: 0.110 cGy) despite patient breathing motion and 
other real world challenges.  Since the 10 cGy point is situated in the region of high dose 
gradient at the edge of the field, patient motion had a greater effect and the six measured 
points averaged 5.90 cGy (standard deviation: 1.01 cGy), a difference that is equivalent 
to approximately a 6 mm shift on the patient’s surface. 
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INTRODUCTION 
 
The long term effects of low dose ionizing radiation (LDIR) on the human body have 
been studied based on data from the survivors of radiological accidents and the atomic 
bomb detonations in Hiroshima and Nagasaki in August 1945.  A linear relationship 
between increased cancer risk and single radiation dose has been established for the dose 
range from 0.5 Sv to approximately 2.5 Sv.  Below 0.5 Sv, theories regarding relative 
biologic effectiveness vary widely from bystander effect, predicting a proportionally 
higher risk from low doses, to hormesis, postulating a positive effect from LDIR.  
Knowledge of the potential biologic effects of LDIR is highly desirable as it impacts risk 
assessment for a range of industrial applications and clinical procedures which use 
ionizing radiation.  Current public policy in the United States is based on the “linear no-
threshold model” which assumes that the effects of LDIR can be estimated by linear 
extrapolation backwards from effects observed for high doses.  A conclusion of this 
model is the belief that there is no safe dose as even very low doses of ionizing radiation 
produce some (assumed negative) biological effect.   
There is ample evidence from in vitro cell culture models that doses as low as 1 cGy 
result in biologic activity (1).  However, the cells used in such studies lack the 
complexity of 3-dimensional tissue.  In addition, cell lines have often been immortalized 
or transformed and live on artificial substrates.  To draw conclusions with respect to the 
effect of LDIR on the human body it is therefore necessary to obtain translational data in 
humans.  It is not possible to irradiate volunteers prospectively for the purpose of such 
studies; however, humans are irradiated daily for the treatment of their cancers, providing 
a population where prospective data can be obtained.  In fact, radiotherapy patient 
volunteers offer a wide range of dose points if the physics and dosimetric support for site 
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identification is sufficiently robust.  As the specimens would be obtained from cancer 
patients receiving therapeutic radiation, the dose delivered cannot be altered for ease of 
scientific protocols.  Consequently, LDIR exposure is generally received outside the 
radiation treatment area, making the dosimetry a significant challenge.   
To assess the biological effects of low dose radiation on humans, skin may be sampled 
outside the primary radiation fields in areas that still receive quantifiable doses (2).  Skin 
is a good model tissue as it is easily accessible for biopsy in the clinic.  Most solid tumors 
arise from epithelial tissue, which is modeled in the skin.  For the biologic studies to 
provide meaningful data, the accuracy of determining the radiation dose to the tissue is 
paramount especially given the expectation of biologic variability.  To increase the 
confidence that the description of the biological effect is a true finding it is important to 
have high confidence in the accuracy of the precision of the low dose exposure.  
Clinical dosimetric treatment planning is focused on the accuracy of dose within 
the primary radiation fields, whose edges are defined at the 50% isodose line by 
convention (3).  For this study, calculation of the dose outside the primary radiation field, 
in the so-called peripheral region, is of foremost interest. The sources of peripheral dose 
are (a) leakage from the treatment unit, (b) scatter from the primary collimator and the 
flattening filter, (c) scatter from the secondary collimators and from beam modifiers such 
as wedges, blocks, and the multileaf collimators (MLC), and (d) internal scatter 
originating in the patient. 
Standard treatment planning systems are based on numerical approximation 
algorithms to calculate the dose within the radiation field fast and reasonably accurately 
for the purposes of the treatment.  They do not attempt to address the dose outside the 
field with as much accuracy.  Analytical algorithms connected with previous work on 
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peripheral dose were designed for radiation protection and therefore did not aim for the 
accuracy currently being sought (4-22). 
In these studies we have used Monte Carlo simulations to obtain the accuracy 
needed for meaningful radiobiologic assessment of LDIR effects in the 1-10 cGy range. 
Given the location and the dose (as low as 0.5% of the prescribed dose), the expected 
uncertainties were higher than the uncertainties accepted within a treatment field.  The 
goal of these studies was to predict sample points on the volunteer patient’s skin surface 
with a dosimetric uncertainty of 15% or better. 
MATERIALS AND METHODS 
 
1. Monte Carlo System  
The PEREGRINE Monte Carlo system was chosen for the study (23).  A research version 
of the system was commissioned to simulate the 18 MV beam of a Varian Clinac 2100 
(Varian Medical Systems, Palo Alto, CA) at the UC Davis Cancer Center.  Simulation 
parameters and machine specific calibration methods are described in reference (23).   
2. Selection of beam shaping mechanism 
Since the points of dose interest were located beyond the field boundaries, the method of 
field shaping needed to be addressed.  While the jaws function as the major field shaping 
tool, there are two options for the secondary field shaping tools at our clinic: Cerrobend ® 
blocks and Multileaf Collimators (MLC).  Blocks shape the radiation field within the 
rectilinear region described by the jaws.  They normally extend only slightly beyond this 
region, under the jaws. Since the dose points of interest are located under the jaw, the 
outside edge of a block would have to be modeled precisely in the Monte Carlo code. 
This is not practical because the blocks are made individually and the position and shape 
of their outer edge vary slightly from case to case.  Another option would be to extend the 
Lehmann  – page 6 
block to cover the area of interest completely, thus eliminating the influence of its outer 
edge.  This proved not to be viable as well, since block weight became excessive and the 
production tolerances were prohibitively high.  MLCs are very reproducible, but Varian’s 
MLC has gear mechanisms and movable banks in the direction of leaf travel which are 
very difficult to model.  Therefore we chose to locate the biopsy points outside the field 
perpendicular to the MLC travel direction.  For the treatment site in the initial study this 
was possible without impacting the overall patient treatment strategy.   
While the positions of the leaves within the field were dictated by the treatment plan, 
there are multiple options for those leaves not involved in field shaping.  Of special 
interest were those leaves under the Y2 jaw1, since the dose points of interest are under 
that jaw.  Due to the construction of the MLC, those leaves could not be completely 
retracted (i.e. be in the “parked” position).  The standard position for them usually 
defaults to be “closed”, abutting at the center line of the field axis (see Figure 1a).  This 
position was not desirable for our measurements because we wanted to position the 
biopsy points along this axis to simplyfy their identification on the patient.  Dose 
accuracy to the degree necessary for studying LDIR at the doses discussed here is 
difficult to achieve in the simulation under abutting rounded edge MLC leaves, due to the 
positioning uncertainty of the leaves.  Two more favorable scenarios are shown in 
Figures 1b and c.  Here the MLC leaves under the Y2 jaw are either open, that is all 
leaves are set to 6 cm from central axis (Figure 1b), or they are closed but abut away 
from the field axis, i.e. the MLC pairs are set to “–7, 7“  (Figure 1c).  Since we did not 
find any dosimetric advantage in the open case, and it  gives slightly more radiation to the 
patient, we used the MLC closed position (Figure 1c) for our studies.  
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3. Beam direction and biopsy site location 
Within a solid tissue equivalent material, the radiation dose inside the field deposited 
from a megavoltage photon beam - starting at the material surface - rises with depth and 
then reaches a plateau followed by a gradual fall off.  The rise is caused by the 
establishment of charged particle equilibrium and the fall-off by attenuation and 
scattering of the primary beam.  The initial approach for the biopsy site selection was to 
use tissue equivalent bolus material on an entry beam to move the skin surface (biopsy 
site) to a location of charged particle equilibrium and dose plateau.  Verifiication 
measurements with a Farmer chamber in a plastic slab phantom revealed that outside the 
field, where the dose points for this study are located, such a plateau area does not exist.  
In fact, we found a moderately steep dose gradient near the entrance surface, which 
would have led to a higher uncertainty in the dose.  Monte Carlo simulations and 
measurements, however, revealed a more favorable dose profile at the location where the 
beam exits the solid material.  We therefore used the beam exit as the site for the biopsies 
(i.e., a posterior beam for biopsy on the patient’s anterior skin).  We also used 
simulations to investigate the effect on the dose of establishing electron equilibrium at the 
exit surface by adding increasing thicknesses of bolus material.  We found that after 
2.5 cm of tissue equivalent material no more change in dose was observed at the material 
(skin) surface.  Thus, a  3 cm thick bolus material over the biopsy site was chosen for 
patient studies.  
4. Confirmatory Measurements with TLDs 
For the purposes of biopsy site selection in patients, Monte Carlo simulations were 
evaluated for their ability to accurately predict the low doses received by the skin outside 
the treatment field.  Therefore, a detector was needed which was sensitive down to 1 cGy, 
Lehmann  – page 8 
while maintaining reasonable accuracy at such low doses. The detector also needed to be 
small in size to avoid dose averaging.  The steep dose gradient outside the field made 
dose averaging a significant potential complication.  Ideally, the detector should be the 
size of the biopsy core, which is three millimeters in diameter.  Thermoluminescent 
dosimeters (TLD) type EXT-RAD 740 (Harshaw – Thermo RMP, 6801 Cochran Road, 
Solon, OH 44139, USA) were used for this study. This model uses a single 7LiF:Mg,Ti 
chip (3x3 mm2, TLD-700 material) permanently mounted on a bar-coded substrate.  The 
chip thickness is 40 mg/cm2, which corresponds to approximately 0.1 mm.  The TLD 
chip-strate is loaded into a sealed pouch with a 0.008-inch thick window over the active 
portion of the TLD.  Since the window is very thin the position of the chip-strate can be 
easily and accurately identified through it.  The TLDs were read using a Harshaw model 
6600 automatic TLD reader.  We calibrated the TLDs using an ion chamber with known 
energy dependence (Farmer chamber) through measurements in a water-equivalent slab 
phantom. The TLDs were used for both experimental verification of our calculation 
methods and to verify the dose given to the patient at the biopsy site(s). 
5. Validation of accuracy of Monte Carlo system 
A newly designed anthropomorphic phantom (24) was used to investigate the accuracy of 
the PEREGRINE Monte Carlo system in predicting the dose outside of the treatment 
field for a single beam and for multiple beams as used in patient treatment.   The phantom 
was produced in cooperation with the manufacturer of the RANDO® Phantoms (The 
Phantom Laboratory, Greenwich, NY).  It has adjustable body thickness to enhance the 
verification by more closely simulating the variation in actual patient body size.  Since 
the intra-phantom scatter is an important contributor to the peripheral dose (18), the 
thickness of the patient was recognized to be of importance and worth investigating.  Our 
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custom phantom consists of tissue equivalent material, sliced in the coronal direction, 
which provides the option of adding or removing slices to create phantoms of different 
thicknesses while maintaining the anthropomorphic shape (Figure 2).  A more detailed 
description of the new phantom can be found elsewhere (24). 
In initial investigations, the ability of the PEREGRINE Monte Carlo system to 
correctly simulate dose outside of the field of a single beam was determined.  Results of 
TLD measurements in the anthropomorphic phantom were compared to Monte Carlo 
simulations, which were based on CT images of the phantom with the bolus as described 
above.  The TLDs were positioned on the anterior side of the phantom at variable 
distances from the field edge under the bolus material (2, 8, 10, 12 cm from central beam 
axis (CAX)).  The beam was applied from the posterior side of the phantom, putting the 
dose points on the beam exit side.  Measurements were performed for four different 
phantom thicknesses (17.9 cm, 25.4 cm, 28.1 cm, 30.7 cm).  An open beam (field size 10 
x 10 cm2, MLC parked) and an MLC shaped beam were investigated.  
Next, multiple beams conditions were verified using the anthropomorphic phantom.  Five 
isocentric fields (gantry angles: 70, 120, 240, 290, and 360 degrees, Varian convention) 
were directed at the phantom with the isocenter positioned about mid-phantom.  The 
fields were realistically shaped using the MLC.  The MLC leafs under the Y jaws were 
closed and abutted on the side (similar to Figure 1c).  Measurements were again 
performed for four different phantom thicknesses using TLDs placed at 2, 8, 10, and 
12 cm from CAX and compared to Monte Carlo simulations based on CT images of the 
phantoms.  All TLD measurements were repeated three times within a measurement 
series, and two to three measurement series were done for every phantom thickness - 
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beam setup combination. Therefore at least six independent TLD measurements were 
performed per data point. 
6. Patient Studies 
Patients consented for the IRB (Institutional Review Board) approved study received an 
extra CT scan with bolus covering the anterior side of the treatment region and extending 
in the superior direction. Based on this CT scan, a treatment plan was created using a 
clinical 510K-cleared treatment planning system similar to the patient’s regular plan and 
approved by the treating physician.  The plan was then submitted for Monte Carlo 
simulation. Following the simulation, the positions of the dose points of interest on the 
skin were identified.  Based on the phantom measurements we multiplied the doses 
outside the beam by a factor of 1.15 for the patient simulations (see results section).  The 
patient volunteers had either one or three biopsies at 1 cGy and one or none at 10 cGy, 
depending on their group within the research protocol.  The sites for biopsy were located 
and marked on the first day of treatment while the patient was in treatment position on 
the linac couch.  A TLD was placed exactly on the position of each biopsy site and 
another one immediately adjacent to it.  TLDs were removed after treatment for readout. 
As detailed elsewhere (2) biopsies were obtained after the first IR fraction.  
Sixteen patients have been irradiated.  Each patient had two or three irradiated biopsy 
locations (in addition to a pre- irradiation biopsy).  A total of 42 measurement points were 
taken. 
RESULTS 
 
Figure 3 shows the agreement of the phantom measurement for a single open beam (10 x 
10 cm2, MLC parked) with the corresponding Monte Carlo simulations.  The difference 
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of Monte Carlo versus measurement is plotted as a function of distance of measurement 
point from the CAX for four phantom thicknesses.  Three of the thicknesses (25.4 cm, 
28.1 cm, 30.7 cm) represent the range of anterior-posterior thicknesses of realistic 
prostate cancer patients. The thinnest version of the phantom (17.9 cm thickness, left 
most drawing in Figure 2) is not clinically relevant and was examined only in order to 
gain insight into simulation-measurement deviation trends.   
For the measurement points outside the field, as shown in Figure 3, Monte Carlo 
simulations are 5% less than measurements for off axis locations greater than 8 cm.  At 
8 cm off axis the agreement is within 3 %, and at a control point inside the field (2 cm of 
CAX, not shown here) the agreement is better than 2%, which is well within the error of 
TLD measurement.   
With a single MLC shaped beam (as in Figure 1c) the deviation of off-axis simulations 
and measurements was greater as shown in Figure 4a.  When examined as a function of 
phantom thickness, simulations increasingly underestimate the dose with decreasing 
phantom thickness (Figure 4b).  
Figure 5 shows agreement for five-beam cases, where four oblique beams are added to 
the PA beam.  All beams are MLC-shaped for a standard prostate cancer treatment in the 
way illustrated in Figure 1c.  These additional beams increase the deviation of the Monte 
Carlo simulations from the measurements to approximately 8-22% with a trend of 
increasing deviation with distance from the CAX.  Figure 5a illustrates the dependence of 
the deviation on the distance of the measurement point from the CAX.  Figure 5b shows 
the relationship between the phantom thickness and the percentage deviation of the 
Monte Carlo simulation and the measurements. For five-field cases significant thickness 
dependence was not observed.   
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While the deviations described above are of scientific interest from a physics research 
perspective, they did not hinder the progress of the biology component of the project. We 
found that within the range of clinical patient thicknesses (phantom thicknesses 25.4-
30.7 cm,) at the doses required for the biologic investigations (1 cGy and 10 cGy), a 
single, thickness- independent correction factor of 1.18 could be applied to the results of 
Monte Carlo simulations to yield a reliable prediction for the biopsy location in a clinical 
setting.   
Figure 6 shows the dose measured at the predicted 1 cGy biopsy points in 16 
(consecutive) patients.  The average dose measured with TLD on the biopsy location 
predicted by the corrected Monte Carlo algorithm to receive 1 cGy was 0.985 cGy 
(Standard deviation: 0.110 cGy).  The additional TLD adjacent to the biopsy location 
measured on average 1.00 cGy (Standard deviation: 0.105 cGy). The data for all 1 cGy 
points is displayed in figure 6 showing an overall very good agreement. 
 
The 10 cGy points presented a greater challenge because the points were located 
within a high dose gradient region.  For the six patients that underwent biopsies for 
10 cGy, the average measured dose at the location of the biopsy was 5.90 cGy (Standard 
deviation: 1.01 cGy) and adjacent to the location 5.84 cGy (Standard deviation: 
1.80 cGy) (see Figure 7).  This deviation is equivalent to an approximately 6 mm shift in 
the biopsy position from the field edge as illustrated for a typical case in Figure 8. 
 
DISCUSSION 
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Translational human data is an essential key in the investigation of the effects of LDIR on 
humans.  In patients receiving therapeutic radiation there exists a wide range of dose 
points, from very low doses through to the maximum dose given in a treatment fraction.  
This range can be used for the in vivo investigation of the effects of low doses of ionizing 
radiation on humans if the biopsy site is accessible in the clinic and if dose prediction at 
the potential biopsy site can be performed accurately.  We have reported details of our 
investigations of the practicality of predicting the location of skin surface dose at 
potential biopsy sites outside the treatment field that receive 1 cGy and 10 cGy for 
prostate radiotherapy patients.   
 
This methodology was sufficiently accurate to support the clinical/biological 
investigations. It also has also revealed interesting discrepancies between Monte Carlo 
simulations and measurements.  The phantom measurements showed that outside the 
field, dose calculation with Monte Carlo simulations are systematically lower than 
measurements using TLDs.  This is true even for the simplest case of a single beam with 
parked MLC (measurements on the beam exit side of the phantom).  The effect is 
noticeable starting between 8 and 10 cm from CAX (10x10 cm2 field).  The deviation 
increases for an MLC shaped beam and even more for a five beam treatment using MLC.  
The deviation is larger as distances increase from the CAX under all examined cases.  
Influence of the phantom thickness was observed for the single beam MLC shaped 
experiments (Fig 4b).  For thicker phantoms the deviation is smaller, indicating that the 
discrepancy stems at least in part from simplifications in the simulation of the accelerator 
head; the longer path of the radiation to the detector through a thicker phantom reduces 
the impact.  This is consistent with the Monte Carlo simulations failing to accurately 
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model dose components originating outside the main beam line in the accelerator head.  
With the addition of the MLCs to the beam shaping and simulations, problems may arise 
from the simulation of either the MLC transmission properties or scatter off the MLCs 
into regions outside the field.  Thicker phantoms have a larger solid angle subtended at 
the TLD and therefore a larger fraction of the dose comes from intra-phantom scatter.  In 
turn, this leads to a smaller dependence on accuracy of simulation of the beam line than 
in the very thin phantom case, consistent with our results.      
 
The addition of oblique beams, as used in the five beam cases, further increases 
the difference between simulation and measurement.  This can be best explained by 
increased accelerator head scatter reaching the measurement points of interest with less 
intra-phantom attenuation, as compared to the AP beam.   
 
Within the parameters of a clinical prostate cancer treatment, a single, thickness-
independent correction factor can be used to identify biopsy locations outside the beam.  
Locations receiving 1 cGy in one fraction of regular 5-beam prostate cancer therapy 
(2 Gy at 95% isodose line) could be identified with high reliability (average dose: 
0.985 cGy, standard deviation: 0.110 cGy, which represents 0.05% of the prescribed 
dose).  Under the same conditions, 10 cGy points are harder to pre-specify since they are 
located in the high dose gradient of the field edge.  This is illustrated in figure 8, which 
shows the dose along the midline of a patient under the bolus material for a single protate 
treatment fraction (2 Gy at 95% isodose line).  The 1 cGy point (filled diamond) is 
located in a low gradient area well outside the field. The 10 cGy point (filled square) is at 
the edge of the field in a very steep dose gradient.  Considering the circumstances of a 
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real-world treatment, including the fact that the patient is breathing, small movements of 
the biopsy site throughout the treatment cannot be avoided.  For the 10 cGy point, 
however, such small movements have drastic consequences.  As shown in figure 8, 
moving the point on the skin by just 6 mm causes the dose received to drop to the 
measured average of 5.9 cGy (open square).  Therefore large percentage deviations 
correspond to only small shifts of the biopsy point with respect to the field edge (about 
6 mm), which are well within the range of expected movement.  Thus, the Monte Carlo 
CT based method of dose prediction  presented here is in itself not sufficient to operate in 
such dose gradients.  A modification of the protocol to address this challenge is under 
development.  However, for the 1 cGy point the present method delivers accuracy with 
high reliability and has allowed important biologic studies to proceed.  
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FIGURE LEGENDS 
FIG. 1.  Schematic of an MLC shaped field with (a) the MLC leaves closed under 
the Y2 jaw in standard 0,0 position, (b) the MLC leaves open under the Y2 jaw and (c) 
the MLC leaves set to –7,7 under the Y2 jaw to avoid abutting the leaves directly over the 
points of interest (filled circles). 
FIG. 2. Custom anthropomorphic phantom with variable thickness.  Shown are 
the thinnest (left) and the thickest (right) version and one in between configuration.  The 
phantom is described in more detail in reference (24). 
FIG. 3. Comparison of the phantom measurements with the corresponding Monte 
Carlo simulations for a single open beam (isocentric setup, 10 x 10 cm2, MLC parked) for 
four phantom configurations: very thin (17.9 cm thick), thin (25.4 cm), medium 
(28.1 cm) and thick (30.7 cm).  The y-axis shows the %difference between simulations 
(PG) and TLD measurements (TLD): (PG-TLD)/TLD.  The x-axis represents the distance 
of measurement point from the CAX.  The error bars shown in this and in all subsequent 
diagrams represent one standard deviation. 
FIG. 4. Comparison of the phantom measurements with the corresponding Monte 
Carlo simulations for a single MLC shaped beam (isocentric setup, 10 x 10 cm2, MLC 
leaves under the jaws closed on the side as in Figure 1c) for four phantom configurations: 
very thin (17.9 cm thick), thin (25.4 cm), medium (28.1 cm) and thick (30.7 cm).  The y-
axis shows the %difference between simulations (PG) and TLD measurements (TLD): 
(PG-TLD)/TLD.  The %difference is plotted as a function of distance of measurement 
point from the CAX for the four phantom thicknesses (a) and as a function of phantom 
thicknesses for three distances of the measurement point from the CAX (b).   
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FIG. 5. Comparison of the phantom measurements with the corresponding Monte 
Carlo simulations for a realistic 5 beam prostate treatment (isocentric setup, 10 x 10 cm2, 
MLC leaves under the jaws closed on the side as in Figure 1c) for four phantom 
configurations: very thin (17.9 cm thick), thin (25.4 cm), medium (28.1 cm) and thick 
(30.7 cm).  The y-axis shows the %difference between simulations (PG) and TLD 
measurements (TLD): (PG-TLD)/TLD.  The %difference is plotted as a function of 
distance of measurement point from the CAX for the four phantom thicknesses (a) and as 
a function of phantom thicknesses for three distances of the measurement point from the 
CAX (b).   
FIG. 6. TLD measurements at locations on patients that were pre-selected to 
receive 1 cGy (filled diamonds) and adjacent to the locations (open squares).  Patients 1-6 
had each one 1 cGy biopsy location, patients 7-16 had each three locations.  Average 
dose on the location was 0.985 cGy (Standard deviation: 0.110 cGy) and adjacent to the 
location 1.00 cGy (Standard deviation: 0.105 cGy).   
FIG. 7. TLD measurements at locations on patients that were pre-selected to 
receive 10 cGy (filled diamonds) and adjacent to the locations (open squares).  Average 
dose on the location was 5.90 cGy (Standard deviation: 1.01 cGy) and adjacent to the 
location 5.84 cGy (Standard deviation: 1.80 cGy).   
FIG. 8. Dose along the midline of a typical patient under the bolus material from 
a single protate treatment (2 Gy at 95% isodose line).  The 1 cGy point (diamond) is 
located in a low gradient area well outside the field. The 10 cGy point (filled square) is at 
the edge of the field in a very steep dose gradient.  The average measurement for the 10 
cGy points (figure 7) was 5.9 cGy (open square), which is for this typical case about 
6 mm away from the location with the desired 10 cGy.  
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FOOTNOTES 
 
                                                 
1 MLC leaf positions are described according to the Varian convention:  The first number 
corresponds to the position of the leaf of the leaf bank A (under X1 jaw) and describes 
the position of this leaf as the distance of its tip from the field midline in the projection to 
the isocenter plane in units of centimeter.  The second number describes the leaf of the 
leaf bank B (under X2 jaw) accordingly.  Negative numbers indicate overtravel, that is a 
leaf crossing the midline. 
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